Testicular Cancer: A Prototypic Tumor of Young Adults

Seminars in Oncology

Volumn 36, Issue 5, 2009, Pages 432-438

  Hayes Lattin, Brandon ^a   Nichols, Craig R ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b EARLE A CHILES RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE;

ARTICLE; BIOLOGY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER SURVIVOR; CLINICAL FEATURE; GERM CELL TUMOR; GLOMERULUS FILTRATION RATE; HEARING LOSS; HUMAN; LUNG DISEASE; LUNG FIBROSIS; LYMPH NODE DISSECTION; MONITORING; NAUSEA; NEUROTOXICITY; NON SEMINOMATOUS GERMINOMA; OTOTOXICITY; PEDIATRICS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; TESTIS CANCER; TUBULAR DYSFUNCTION;

ADULT; AGE DISTRIBUTION; HUMANS; INCIDENCE; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; ORCHIECTOMY; PROGNOSIS; SEER PROGRAM; TESTICULAR NEOPLASMS; UNITED STATES; YOUNG ADULT;

EID: 70349759471     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2009.07.006     Document Type: Article

References (33)

1. Ries L.A.G., Melbert D., Krapcho M., Stinchcomb D.G., Howlader N., Horner M.J., et al. SEER cancer statistics review, 1975-2005. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2005/ posted to the SEER website, 2008
2. Fallon R., Olson A., and Saxman S. Male genital tract cancer. In: Bleyer A., O'Leary M., and Barr R. (Eds). Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000. NIH Pub. No. 06-5767 (2006), National Cancer Institute, Bethesda, MD
3. Chaganti R.S., Rodriguez E., and Bosl G.J. Cytogenetics of male germ cell tumors. Urol Clin North Am 20 (1993) 55-66
4. Houldsworth J., Korkola J.E., Bosl G.J., and Chaganti R.S. Biology and genetics of adult male germ cell tumors. J Clin Oncol 24 (2006) 5512-5518
5. Dow J.A., and Mostofi F.K. Testicular tumors following orchioplexy. South Med J 60 (1967) 193-195
6. Tollerud D.J., Blattner W.A., Fraser M.C., Brown L.M., Pottern L., Shapiro E., et al. Familial testicular cancer and urogenital developmental anomalies. Cancer 55 (1985) 1849-1854
7. Raghavan D., Zalcberg J.R., Grygiel J.J., Teriana N., Cox K.M., McCarthy W., et al. Multiple atypical nevi: a cutaneous marker of germ cell tumors. J Clin Oncol 12 (1994) 2284-2287
8. Nichols C.R., Heerema M.A., Palmer C., Loehrer P.J., Williams S.D., Einhorn L.H., et al. Klinefelter's syndrome associated with mediastinal germ cell neoplasms. J Clin Oncol 5 (1987) 1290-1294
9. Carver B.S., Serio A.M., Bajorin D., Motzer R.J., Stasi J., Bosl G.J., et al. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. J Clin Oncol 25 (2007) 5603-5608
10. American Joint Committee on Cancer. Testis. In: Fleming I.D., Cooper J.S., Henson D.E., Hutter R.V., Kennedy B.J., and Murphy S.P. (Eds). AJCC cancer staging manual. 5th ed. (1997), Lippincott-Raven, Philadelphia 225-230
11. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15 (1997) 594-603
12. Moore C.J., Daneshmand S., Hayes-Lattin B., Stott W., and Nichols C.R. Outcomes of surveillance in unselected patients with clinical stage I testicular germ cell tumors: results of a modern single institution series. [abstract 5085]. J Clin Oncol 25 (2007) 18S
13. Groll R.J., Warde P., and Jewett M.A. A comprehensive systemic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol 64 (2007) 182-197
14. Olson T.A., Cullen J.W., Lauer S.J., Giller R.H., Cushing B., Rogers P.C., et al. Low dose bleomycin every three weeks with cisplatin and etoposide results in excellent event free survival and survival in children and adolescents with gonadal malignant germ cell tumors (MGCT). A POG/CCG study. [abstract 3207]. Proc Am Soc Clin Oncol 22 (2003) 798
15. Williams S.D., Birch R., Einhorn L.H., Irwin L., Greco F.A., Loehrer P.J., et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316 (1987) 1435-1440
16. de Wit R., Roberts J.T., Wilkinson P.M., de Mulder P.H., Mead G.M., Fossa S.D., et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19 (2001) 1629-1640
17. Bajorin D.F., Geller N.L., Weisen S.F., and Bosl G.J. Two-drug therapy in patients with metastatic germ cell tumors. Cancer 67 (1991) 28-32
18. Steele G.S., Richie J.P., Stewart A.K., and Menck H.R. The National Cancer Data Base report on patterns of care for testicular carcinoma, 1985-1996. Cancer 86 (1999) 2171-2183
19. Oliver R.T., Mason M.D., Mead G.M., von der Maase H., Rustin G.J., Joffe J.K., et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomized trial. Lancet 366 (2005) 293-300
20. Horwich A., Oliver R.T., Wilkinson P.M., Mead G.M., Harland S.J., Cullen M.H., et al. A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. Br J Cancer 83 (2000) 1623-1629
21. Hayes-Lattin B., and Nichols C.R. Hematopoietic cell transplantation in germ cell tumors. In: Blume K.G. (Ed). Thomas' hematopoietic cell transplantation. 3rd ed. (2004), Blackwell Publishing, Boston 1308-1319
22. Gritz E.R., Wellisch D.K., and Landsverk J.A. Psychosocial sequelae in long-term survivors of testicular cancer. J Psychosoc Oncol 6 (1988) 41-63
23. Gritz E.R., Wellisch D.K., Wang H.J., Siau J., Landsverk J.A., and Cosgrove M.D. Long-term effects of testicular cancer on sexual functioning in married couples. Cancer 64 (1989) 1560-1567
24. Fossa S.D., Aass N., Winderen M., Bormer O.P., and Olsen D.R. Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol 13 (2002) 222-228
25. Reddel R.R., Kefford R.F., Grant J.M., Coates A.S., Fox R.M., Tattersall M.H., et al. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep 66 (1982) 19-23
26. Thompson S.W., Davis L.E., Kornfeld M., Hilgers R.D., and Standefer J.C. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 54 (1984) 1269-1275
27. Haugnes H.S., Aass N., Fossa S.D., Dahl O., Brydoy M., Aasebo U., et al. Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol 27 (2009) 2779-2786
28. Vogelsang N.J., Bosl G.J., Johnson K., and Kennedy B.J. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Lancet 2 (1981) 970-973
29. Doll D.C., List A.F., Greco F.A., Hainsworth J.D., Hande K.R., Johnson D.H., et al. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 105 (1986) 48-51
30. Haugnes H.S., Aass N., Fossa S.D., Dahl O., Klepp O., Wist E.A., et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 18 (2007) 241-248
31. Pedersen-Bjergaard J., Philip P., Larsen S.O., Andersson M., Daugaard G., Ersboll J., et al. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 7 (1993) 1975-1986
32. Hendry W.F., Stedronska J., Jones C.R., Blackmore C.A., Barrett A., Peckham M.J., et al. Semen analysis in testicular cancer and Hodgkin's disease: pre- and posttreatment findings and implications for cryopreservation. Br J Urol 55 (1983) 769-773
33. Lampe H., Horwich A., Norman A., Nicholls J., and Dearnaley D.P. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 15 (1997) 239-245